| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 4
| Issue : 5 | Page : 21-24 |
|
|
The Current Use of Anti-IL6 and Corticosteroids in COVID-19 Patients with Cytokine-Release Syndrome
Marwa Amer1, Mohammed Bawazeer2, Talal Dahhan2, Eiad Kseibi2, Abid Butt2, Mohammed Abujazar2, Razan Alghunaim1, Muath Rabee2, Syed Moazzum Khurshid2
1 Division of Pharmaceutical Care, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
2 Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Correspondence Address:
Marwa Amer
Division of Pharmaceutical Care, College of Medicine, Alfaisal University, MBC #11, King Faisal Specialist Hospital and Research Center, PO Box: 3354, Riyadh 11211
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/sccj.sccj_38_20
|
|
|
Cytokine-release syndrome (CRS) includes overproduction of inflammatory cytokines, termed a “cytokine storm,” which has been observed in a large proportion of critically ill COVID-19 patients. Patients diagnosed with CRS rapidly progress to cardiovascular collapse and multi-organ failure and carry a high mortality rate. Therefore, early detection, treatment, and prevention of cytokine storms are important. Immunomodulators, such as interleukin-6 (IL-6) antagonists, have recently emerged as an alternative therapeutic option for COVID-19 patients with cytokine storms. In preparation for a clinical trial, we searched the PUBMED, EMBASE, and COCHRANE databases to obtain related publications on the use of immunotherapies in CRS and CRS with COVID-19. We also included major review articles and recent guidelines. In our proposal, we aim to evaluate the efficacy and safety of anti-IL-6 alone versus anti-IL-6 and corticosteroid combination in COVID-19 critically ill patients with CRS. Our primary outcomes are duration of mechanical ventilation and 28-day ventilator-free days.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
